英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • CHAPLE Disease Treatment | VEOPOZ (TM) (pozelimab-bbfg)
    VEOPOZ is the first and only FDA-approved treatment for CHAPLE disease 1 VEOPOZ is a complement inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with a disease called CD55-deficient protein-losing enteropathy, also known as CHAPLE disease 1
  • VEOPOZ Full Prescribing Information - Regeneron Pharmaceuticals
    VEOPOZ for subcutaneous use must be prepared and administered by a healthcare provider Preparation Instructions for Subcutaneous Maintenance Dose 1 Remove VEOPOZ vial(s) from refrigeration and allow the vial(s) to sit for at least 45 minutes at room temperature 20°C to 25°C (68°F to 77°F) before use 2
  • Pozelimab - Wikipedia
    Pozelimab, sold under the brand name Veopoz, is a recombinant monoclonal antibody used for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease [1] [2] Pozelimab is a complement inhibitor [1] [2] It is produced using recombinant DNA technology in Chinese hamster ovary cells [1]The most common adverse reactions include upper respiratory tract infections
  • Veopoz Uses, Dosage, Side Effects, Warnings - Drugs. com
    Veopoz and other medicines may affect each other, causing side effects Veopoz may affect the way other medicines work, and other medicines may affect how Veopoz works including prescription and over-the-counter medicines, vitamins, and herbal supplements Especially tell your healthcare provider if you take Intravenous Immunoglobulin (IVIg)
  • FDA approves first treatment for CD55-deficient protein-losing
    The efficacy and safety of Veopoz was evaluated in a single-arm study (NCT04209634), in which patients’ outcomes were compared to pre-treatment data in patients with active CD55-deficient
  • Veopoz (Pozelimab Injection): Side Effects, Uses, Dosage . . . - RxList
    VEOPOZ is a medicine that affects your immune system VEOPOZ can lower the ability of your immune system to fight infections VEOPOZ increases your chance of getting serious and life-threatening meningococcal infections Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early
  • FDA Approves Pozelimab (Veopoz) as First Treatment for . . . - HCP Live
    The US Food and Drug Administration (FDA) has approved pozelimab-bbfg (Veopoz) for the treatment of for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease Announced by Regeneron on August 18, 2023, the approval makes pozelimab-bbfg the first and only treatment indicated specifically for CHAPLE disease, which is also known as CD55-deficient protein
  • Veopoz (pozelimab-bbfg) – New orphan drug approval - OptumRx
    • Veopoz is a monoclonal antibody designed to block the activity of complement factor C5 • The efficacy of Veopoz was established in a single-arm study where outcomes were compared to pre-treatment data in patients with active CD55-deficient PLE who had hypoalbuminemia
  • FDA Approves Regeneron’s Veopoz as the First Treatment . . . - Global Genes
    Veopoz was previously granted Rare Pediatric Disease designation, Orphan Disease designation and Fast Track designation As part of its ongoing development program, Veopoz is also being evaluated in combination with Alnylam’s cemdisiran as an investigational combination therapy for the treatment of other complement-mediated disorders
  • Pozelimab: First Approval - PubMed
    Pozelimab (pozelimab-bbfg; VEOPOZ™) is a fully human immunoglobulin (Ig) G4 P (i e IgG4 with a proline substitution to promote stabilization of the disulfide bonds between the two heavy chains) monoclonal antibody developed by Regeneron Pharmaceuticals Inc , to block the activity of complement factor 5 (C5) and prevent diseases mediated by the complement pathway





中文字典-英文字典  2005-2009